Cited by 1,357RNA Interference and Gene DeliveryVirus-based gene therapy researchRNA Research and Splicing

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

RNAi-mediated gene silencing in non-human primates

Zimmermann, Tracy S., Lee, Amy C. H., Akinc, Akin, Bramlage, Birgit, Bumcrot, David, Fedoruk, Matthew N., Harborth, Jens, Heyes, James A., Jeffs, Lloyd B., John, Matthias, Judge, Adam D., Lam, Kieu, McClintock, Kevin, Nechev, Lubomir V., Palmer, Lorne R., Racie, Timothy, Röhl, Ingo, Seiffert, Stephan, Shanmugam, Sumi, Sood, Vandana, Soutschek, Jürgen, Toudjarska, Ivanka, Wheat, Amanda J., Yaworski, Ed, Zedalis, William, Koteliansky, Victor, Manoharan, Muthiah, Vornlocher, Hans-Peter, MacLachlan, Ian·2006·Nature

DOI 10.1038/nature04688

Open this paper in CoChat — free account

Abstract

The opportunity to harness the RNA interference (RNAi) pathway to silence disease-causing genes holds great promise for the development of therapeutics directed against targets that are otherwise not addressable with current medicines. Although there are numerous examples of in vivo silencing of target genes after local delivery of small interfering RNAs (siRNAs), there remain only a few reports of RNAi-mediated silencing in response to systemic delivery of siRNA, and there are no reports of systemic efficacy in non-rodent species. Here we show that siRNAs, when delivered systemically in a liposomal formulation, can silence the disease target apolipoprotein B (ApoB) in non-human primates. APOB-specific siRNAs were encapsulated in stable nucleic acid lipid particles (SNALP) and administered by intravenous injection to cynomolgus monkeys at doses of 1 or 2.5 mg kg(-1). A single siRNA injection resulted in dose-dependent silencing of APOB messenger RNA expression in the liver 48 h after administration, with maximal silencing of >90%. This silencing effect occurred as a result of APOB mRNA cleavage at precisely the site predicted for the RNAi mechanism. Significant reductions in ApoB protein, serum cholesterol and low-density lipoprotein levels were observed as early as 24 h after treatment and lasted for 11 days at the highest siRNA dose, thus demonstrating an immediate, potent and lasting biological effect of siRNA treatment. Our findings show clinically relevant RNAi-mediated gene silencing in non-human primates, supporting RNAi therapeutics as a potential new class of drugs.

Integrity signals

Registry

Crossref · 10.1038/nature04688

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,206
Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7
Hornung, V., Guenthner‐Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A. M., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,261
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,260
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K. S., Jensen, K., Breen, W., Hartsough, K. C., Machemer, L., Radka, S. F., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,175
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,027
The RNAi revolution
Novina, C. D., & Sharp, P. A. (2004) · Nature · doi:10.1038/430161a · Cited by 739
Inhibition of respiratory viruses by nasally administered siRNA
Bitko, V., Musiyenko, A., Shulyayeva, O., & Barik, S. (2004) · Nature Medicine · doi:10.1038/nm1164 · Cited by 731

Show all 20 references

Sorted by citations

Items 901–1,000 of 1,001

Lipid nanoparticle mediated small interfering RNA delivery as a potential therapy for Alzheimer's disease
Ahmed, T. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16336 · Cited by 18
“The confluence of these advances in technology culminated in the very first evidence of effective RNA interference in primates that were not humans in the year 2006 (Zimmermann et al., 2006).”
Background
pH‐Cleavable Nucleoside Lipids: A New Paradigm for Controlling the Stability of Lipid‐Based Delivery Systems
Oumzil, K., Benizri, S., Tonelli, G., Staedel, C., Appavoo, A., Chaffanet, M., Navailles, L., & Barthélémy, P. (2015) · ChemMedChem · doi:10.1002/cmdc.201500381 · Cited by 15
New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases
Koenig, O., Walker, T., Perle, N., Zech, A., Neumann, B., Schlensak, C., Wendel, H.-P., & Nolte, A. (2013) · Pharmaceuticals · doi:10.3390/ph6070881 · Cited by 15
“As a consequence the LDL was reduced over the 11-day study and no complement activation, pro-inflammatory cytokine production or toxicities have been observed [16].”
Background
Gene silencing and antitumoral effects of Eg5 or Ran siRNA oligoaminoamide polyplexes
Edinger, D., Kläger, R., Troiber, C., Dohmen, C., & Wagner, E. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0146-y · Cited by 15
“Advances in carrier design, mainly including polymers [6–8] and liposomes [9, 10] show the potential to overcome”
Therapeutic effect for liver-metastasized tumor by sequential intravenous injection of anionic polymer and cationic lipoplex of siRNA
Hattori, Y., Arai, S., Kikuchi, T., Ozaki, K., Kawano, K., & Yonemochi, E. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1070856 · Cited by 15
Tumor Chemosensitization through Oncogene Knockdown Mediated by Unique α-Tocopherylated Cationic Geminis
Kamra, M., Maiti, B., Dixit, A., Karande, A. A., & Bhattacharya, S. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.8b01751 · Cited by 15
Surface Functionalization of Organosilica Nanoparticles With Au Nanoparticles Inhibits Cell Proliferation and Induces Cell Death in 4T1 Mouse Mammary Tumor Cells for DNA and Mitochondrial-Synergized Damage in Radiotherapy
Mochizuki, C., Kayabe, Y., Nakamura, J., 加藤, 茂., Igase, M., Mizuno, T., & Nakamura, M. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.907642 · Cited by 15
Small interfering ribonucleic acid design strategies for effective targeting and gene silencing
Malhotra, M., Nambiar, S., Rengaswamy, V., & Prakash, S. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.555394 · Cited by 15
“Owing to the transient nature of siRNA, the most common siRNA-delivery methods used are liposomes [90,91], cationic lipids [92,93], lipid conjugant, and stable nucleic acid lipid conjugates [94,95], and polymers such as poly-L-lysine, polyamidoamine dendrimers [96,97] and polyethyleneimine have been widely used for nu…”
Background
Rescue of Pituitary Function in a Mouse Model of Isolated Growth Hormone Deficiency Type II by RNA Interference
Shariat, N. W., Ryther, R. C. C., Phillips, J. A., Robinson, I. C. A. F., & Patton, J. G. (2007) · Endocrinology · doi:10.1210/en.2007-1360 · Cited by 15
Protein-based vehicles for biomimetic RNAi delivery
Pottash, A. E., Kuffner, C. J., Noonan-Shueh, M., & Jay, S. M. (2019) · Journal of Biological Engineering · doi:10.1186/s13036-018-0130-7 · Cited by 15
“Especially of note is the knockdown of apolipoprotein B (ApoB) in non-human primates via chol-siRNA injection in 2006 by Zimmermann et al [38].”
Method
Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice
Dallas, A., Ilves, H., Shorenstein, J., Judge, A. D., Spitler, R., Contag, C. H., Wong, S. P., Harbottle, R. P., MacLachlan, I., & Johnston, B. H. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.50 · Cited by 15
Targeted Comparative RNA Interference Analysis Reveals Differential Requirement of Genes Essential for Cell Proliferation
Machida, Y., Chen, Y., Machida, Y., Malhotra, A., Sarkar, S., & Dutta, A. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-04-0340 · Cited by 15
Designing siRNA that distinguish between genes that differ by a single nucleotide
Schwarz, D. S., Ding, H., Kennington, L. A., Moore, J. T., Schelter, J. M., Burchard, J., Linsley, P. S., D, N. A. M., Xu, Z., & Zamore, P. D. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0020140.eor · Cited by 15
Nanomaterials for chronic inflammatory diseases: the current status and future prospects
Oshi, M. A., Haider, A., Siddique, M. I., Zeb, A., Jamal, S. B., Khalil, A. A. K., & Naeem, M. (2021) · Applied Nanoscience · doi:10.1007/s13204-021-02019-8 · Cited by 14
In vivo PAR-CLIP (viP-CLIP) of liver TIAL1 unveils targets regulating cholesterol synthesis and secretion
Vatandaslar, H., Garzia, A., Meyer, C., Godbersen, S., Brandt, L. T. L., Griesbach, E., Chao, J. A., Tuschl, T., & Stoffel, M. (2023) · Nature Communications · doi:10.1038/s41467-023-39135-8 · Cited by 13
Bivalent mRNA vaccines against three SARS-CoV-2 variants mediated by new ionizable lipid nanoparticles
Wang, J., Zhang, Y., Dong, S., Zha, W., Liu, C., Wang, Y., Jiang, Y., Xing, H., & Li, X. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123155 · Cited by 15
Cardiac gene delivery using ultrasound: State of the field
Singh, D., Memari, E., He, S., Yusefi, H., & Helfield, B. L. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101277 · Cited by 14
“23 While there is much investigation into the lipid composition and overall design of gene-bearing LNPs, this approach is still limited in the context of CVD; including the resulting immune response to LNP formulations of RNA and DNA, and challenged by delivery to non-hepatocyte tissues, in part…”
Background
Advances in the development of lipid nanoparticles for ophthalmic therapeutics
Chen, S., Deng, Z., & Ji, D. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117108 · Cited by 16
Emerging options in the treatment of dyslipidemias: a bright future?
Florentin, M., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.554395 · Cited by 14
“Small apo B-specific interfering RNAs have been shown to decrease plasma cholesterol and apo B levels in animal models [211,212].”
Background
Cellular environment-responsive nanomaterials for use in gene and siRNA delivery: molecular design for biomembrane destabilization and intracellular collapse
Tanaka, H., Sato, Y., Harashima, H., & Akita, H. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1154531 · Cited by 15
Therapeutic Potentials of Noncoding RNAs: Targeted Delivery of ncRNAs in Cancer Cells
Liu, Y., & Wang, J. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-1498-7_16 · Cited by 14
University Technology Transfer Has Failed to Improve Access to Global Health Products during the COVID-19 Pandemic
Herder, M., Gold, E. R., & Murthy, S. (2022) · Healthcare policy · doi:10.12927/hcpol.2022.26830 · Cited by 14
Advances, Nuances, and Potential Pitfalls When Exploiting the Therapeutic Potential of RNA Interference
Battistella, M., & Marsden, P. A. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.8 · Cited by 15
“(PCSK9- known as ALN-PCS) showed a significant low-density lipoprotein (LDL)-lowering effect.(57,58) Genetic studies have supported the hypothesis that lowering of PCSK9 by inhibiting its”
Background
Progress towards Therapeutic Application of RNA Interference for HIV Infection
Singh, S. K., & Gaur, R. K. (2009) · BioDrugs · doi:10.2165/11317120-000000000-00000 · Cited by 14
Influence of lipoplex surface charge on siRNA delivery: application to the in vitro downregulation of CXCR4 HIV-1 co-receptor
Lavigne, C., Slater, K., Gajanayaka, N., Duguay, C., Peyrotte, E. A., Fortier, G., Simard, M., Kell, A., Barnes, M. L., & Thierry, A. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.743526 · Cited by 16
“siRNAs received intense investigation since they have shown the capacity to recognize and degrade, in a sequencespecific manner, an aimed messenger RNA [7-9].”
Background
A Bifurcated Proteoglycan Binding Small Molecule Carrier for si RNA Delivery
Gooding, M., Adigbli, D. K., Chan, A. W. E., Melander, R. J., MacRobert, A. J., & Selwood, D. L. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12295 · Cited by 14
“Cationic polymers such as polyethyleneimine (13), lipids (5,6,14), and cell-penetrating peptides (CPPs), including penetratin (15), polyarginine (16), and MPG (17) have been used to deliver siRNA in vivo, and form complexes via electrostatic interactions which neutralize the charge of the oligonucleotide and allow int…”
Background
A biodistribution study of solid lipid-polyethyleneimine hybrid nanocarrier for cancer RNAi therapy
Xue, H. Y., Tran, N., & Wong, H. L. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.08.014 · Cited by 14
ECAT1 is essential for human oocyte maturation and pre-implantation development of the resulting embryos
Liu, C., Li, M., Li, T., Zhao, H., Huang, J., Wang, Y., Gao, Q., Yu, Y., & Shi, Q. (2016) · Scientific Reports · doi:10.1038/srep38192 · Cited by 15
“…or immunohistochemical staining revealed that these factors are primarily localized throughout the cytoplasm 15,24,27–31, 33, RNAi is a powerful technology that can rapidly suppress specific genes through double-stranded short interfering RNAs (siRNAs) to learn the function of these genes 37–41 .”
RNA and CRISPR Interferences: Past, Present, and Future Perspectives
Sioud, M. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0290-4_1 · Cited by 14
cRGD Grafted siRNA Nano-constructs for Chemosensitization of Gemcitabine Hydrochloride in Lung Cancer Treatment
Khatri, N., Rathi, M. N., Baradia, D., & Misra, A. R. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1351-1 · Cited by 14
MCT4 knockdown by tumor microenvironment-responsive nanoparticles remodels the cytokine profile and eradicates aggressive breast cancer cells
Abdellatif, A. A. H., Bouazzaoui, A., Tawfeek, H. M., & Younis, M. A. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.113930 · Cited by 13
Tissue-specific gene silencing monitored in circulating RNA
Sehgal, A., Chen, Q., Gibbings, D., Sah, D. W. Y., & Bumcrot, D. A. (2013) · RNA · doi:10.1261/rna.042507.113 · Cited by 13
“…to confirm the RNA interference mechanism by identification of the predicted siRNA cleavage product in a number of preclinical and clinical studies (Zimmermann et al. 2006; Frank- Kamenetsky et al. 2008; Querbes et al. 2009; Davis et al. 2010), including detection of circulating siRNA cleavage in…”
BackgroundMethod
Non-viral nucleic acid therapeutics: Revolutionizing the landscape of atherosclerotic treatment
Qu, S., Liu, R., Zhang, N., Xu, Y., Yue, X., & Dai, Z. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101514 · Cited by 14
Synthesis and Biological Activity of Short Interfering RNAs Having Several Consecutive Amide Internucleoside Linkages
Kotikam, V., Viel, J. A., & Rozners, E. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201903754 · Cited by 13
Nanomedicinal delivery approaches for therapeutic siRNA
Keller, M. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.03.038 · Cited by 13
Devouring Atherosclerotic Plaques: The Engineered Nanorobot Rousing Macrophage Efferocytosis by a Two‐Pronged Strategy
Zheng, J., Li, Y., Ge, X., Zhang, G., Wang, Y., Nawsherwan, N., Yu, S., Dai, C., & Sang, M. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202415477 · Cited by 14
Amelioration of Colorectal Cancer Using Negative Lipidoid Nanoparticles to Encapsulate siRNA Against APRIL by Enema Delivery Mode
Ding, W., Wang, G., Shao, K., Wang, F., Huang, H., Ju, S., Cong, H., & Wang, H. (2014) · Pathology & Oncology Research · doi:10.1007/s12253-014-9779-5 · Cited by 12
“To date, the use of non-viral DDSs is preferred because it offers greater safety for clinical application than does the use of viral DDSs, and the non-viral DDSs includes direct conjugation of delivery agents to the RNA moiety [21], formulation using lipid-[22, 23], polymer-[24, 25] or peptide-based delivery systems […”
Background
Silencing inducible nitric oxide synthase protects rat pancreatic islet
Li, B., Liu, Y., & Ying, C. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.05.013 · Cited by 12
Non-viral siRNA delivery vectors: dendritic molecular transporter and molecular transporter nanovectors for target gene silencing
Hamilton, S. K., Sims, A. L., Donavan, J., & Harth, E. M. (2010) · Polymer Chemistry · doi:10.1039/c0py00342e · Cited by 12
TRAIL and microRNAs in the treatment of prostate cancer: therapeutic potential and role of nanotechnology
Farooqı, A. A., & Rosa, G. D. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-5227-9 · Cited by 12
“It is also involved in the negative regulation of Bcl-2.”
BackgroundInfluential
RNA therapy for polyglutamine neurodegenerative diseases
Watson, L. M., & Wood, M. J. A. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2011.1 · Cited by 12
Multifunctional Enveloped Nanodevices (MENDs)
Sato, Y., Nakamura, T., Yamada, Y., Akita, H., & Harashima, H. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00006-7 · Cited by 13
Efficient in vitro delivery of Noggin siRNA enhances osteoblastogenesis
Ghadakzadeh, S., Hamdy, R. C., & Tabrizian, M. (2017) · Heliyon · doi:10.1016/j.heliyon.2017.e00450 · Cited by 12
“LNPs are presently the principal delivery systems that utilize the therapeutic potential of siRNA in cells (Davidson and McCray, 2011; Zimmermann et al., 2006).”
Background
Cytoplasm-Responsive Delivery Systems for siRNA Using Cell-Penetrating Peptide Nanomicelles
Okada, H., Ogawa, T., Tanaka, K., Kanazawa, T., & Takashima, Y. (2014) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(14)50001-9 · Cited by 12
Targeting the serrated pathway of colorectal cancer with mutation in BRAF
Matos, P., Gonçalves, V., & Jordan, P. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.06.003 · Cited by 13
DNA/RNA-based formulations for treatment of breast cancer
Xie, Z., & Zeng, X. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1317744 · Cited by 12
“More recently, the PEGylated cationic liposomes termed as ‘stable nucleic acid lipid particles’ have demonstrated efficacy for gene delivery in several models with improved pharmacokinetics and less toxicity [40], and the synthetic lipidoids incorporated liposomes also have significantly promoted the gene silencing of…”
Background
siRNA-based topical microbicides targeting sexually transmitted infections.
Katakowski, J. A., & Palliser, D. (2010) · PubMed · Cited by 12
Delivery of Nucleic Acids and Gene Delivery
Akita, H., Hatakeyama, H., Khalil, I. A., Yamada, Y., & Harashima, H. (2011) · Elsevier eBooks · doi:10.1016/b978-0-08-055294-1.00150-1 · Cited by 12
TransKingdom RNA interference: a bacterial approach to challenges in RNAi therapy and delivery
Keates, A. C., Fruehauf, J. H., Xiang, S., & Li, C. J. (2008) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-25-113 · Cited by 11
MicroRNAs in Leukemias: Emerging Diagnostic Tools and Therapeutic Targets
Mian, Y. A., & Zeleznik‐Le, N. J. (2010) · Current Drug Targets · doi:10.2174/138945010791320872 · Cited by 12
Glioma Growth Inhibition In Vitro and In Vivo by Single Chain Variable Fragments of the Transferrin Receptor Conjugated to Survivin Small Interfering RNA
Wang, F., Bai, H.-R., Wang, J., Bai, Y.-Z., & Dou, C. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900512 · Cited by 12
Targeting Oncogenes with siRNAs
Heidenreich, O. T. (2008) · Methods in molecular biology · doi:10.1007/978-1-60327-547-7_11 · Cited by 12
LDL-C-Lowering therapy: Current and future therapeutic targets
Visser, M. E., Jakulj, L., Kastelein, J. J. P., & Stroes, E. S. G. (2008) · Current Cardiology Reports · doi:10.1007/s11886-008-0080-7 · Cited by 12
Hsp40s play distinct roles during the initial stages of apolipoprotein B biogenesis
Kumari, D., Fisher, E. A., & Brodsky, J. L. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e21-09-0436 · Cited by 11
“Coronary artery disease (CAD) is the most common form of cardiovascular disease and arises when arteries narrow due to the deposition of cholesterol-filled macrophages that form plaques.”
BackgroundInfluential
Vaccine Formulation Strategies and Challenges Involved in RNA Delivery for Modulating Biomarkers of Cardiovascular Diseases: A Race from Laboratory to Market
Shaharyar, M. A., Bhowmik, R., Al-Abbasi, F. A., AlGhamdi, S. A., Alghamdi, A. M., Sarkar, A., Kazmi, I. A., & Karmakar, S. (2023) · Vaccines · doi:10.3390/vaccines11020241 · Cited by 12
From Basic to Breakthroughs: The Journey of Microfluidic Devices in Hydrogel Droplet Generation
Hinojosa-Ventura, G., Acosta-Cuevas, J. M., Carriles, C. A. V., Navarro-López, D. E., Lopez-Alvarez, M. A., la Rosa, N. D. O.-D., & Jara, J. M. S. (2025) · Gels · doi:10.3390/gels11050309 · Cited by 11
“Various writers have employed liposomes for the release of RNA [43,44].”
Quantitative Analysis of Dicer Substrate Oligonucleotides in Mouse Liver by Ultra-High-Performance Liquid Chromatography–Electrospray Ionization Tandem Mass Spectrometry
Jiao, K., Rashid, A., Basu, S. K., Zhu, S., Brown, B. D., Guerciolini, R., & Fambrough, D. M. (2011) · Assay and Drug Development Technologies · doi:10.1089/adt.2011.0435 · Cited by 11
“For PK study, the HPRT1 DsiRNA was formulated in stable nucleic acid lipid particles 28 and administered at a concentration of 1 mg of DsiRNA/mL of phosphate-buffered saline.”
Combined Lentiviral and RNAi Technologies for the Delivery and Permanent Silencing of the hsp25 Gene
Kaur, P., Nagaraja, G. M., & Asea, A. A. A. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-295-3_10 · Cited by 11
Polyamine-RNA-membrane interactions: From the past to the future in biology
Acosta‐Andrade, C., Artetxe, I., Lete, M. G., Monasterio, B. G., Ruiz‐Mirazo, K., Goñi, F. M., & Sánchez‐Jiménez, F. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.04.005 · Cited by 11
“oligonucleotides for immune therapy (73), and ribozymes and siRNA for gene silencing (74, 75).”
Background
Liquid chromatographic separation of oligonucleotides
Biba, M., Foley, J. P., & Welch, C. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805392-8.00006-2 · Cited by 11
In vivo imaging of the systemic delivery of small interfering RNA
Ifediba, M. A., & Moore, A. V. (2012) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1158 · Cited by 11
Silencing Sexually Transmitted Infections: Topical siRNA-Based Interventions for the Prevention of HIV and HSV
Wheeler, L. A. (2014) · Infectious Diseases in Obstetrics and Gynecology · doi:10.1155/2014/125087 · Cited by 11
Detection of siRNA-mediated target mRNA cleavage activities in human cells by a novel stem-loop array RT-PCR analysis
Lin, J., Xu, K., Roth, J. A., & Ji, L. (2016) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2016.02.012 · Cited by 11
RNA interference in the treatment of renal stone disease: Current status and future potentials
Wood, K. D., Holmes, R. P., & Knight, J. L. (2016) · International Journal of Surgery · doi:10.1016/j.ijsu.2016.11.027 · Cited by 11
“This interaction with the mRNA results in degradation and suppression and thus decreased target protein expression [4].”
Background
Prospect and progress of gene therapy in treating atherosclerosis
Kivelä, A. M., Huusko, J., & Ylä‐Herttuala, S. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1084282 · Cited by 11
“Liver-directed siRNAs against ApoB were shown to reduce total cholesterol levels in mice by 70% [18], whereas stable nucleic acid lipid particle (SNALP) encapsulated ApoB siRNAs reduced total cholesterol by 62% in nonhuman primates [19].”
Background
Synthesis, RNAi activity and nuclease-resistant properties of apolar carbohydrates siRNA conjugates
Vengut‐Climent, E., Terrazas, M., Lucas, R., Arévalo‐Ruiz, M., Eritja, R., & Morales, J. C. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.065 · Cited by 11
Neuroprotective Effect of Small Interfering RNA Targeted to Caspase-3 on Rat Retinal Ganglion Cell Loss Induced by Ischemia and Reperfusion Injury
Ishikawa, S., Hirata, A., Nakabayashi, J., Iwakiri, R., & Okinami, S. (2012) · Current Eye Research · doi:10.3109/02713683.2012.688161 · Cited by 11
“[13] Zimmermann TS, Lee AC, Akinc A et al.”
Background
Gene delivery platforms
Kim, J., Shin, E., Ryou, S.-M., Yeom, J., & Lee, K. (2013) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-012-0546-8 · Cited by 11
“Commonly used cationic liposomes include zwitterionic lipid, the cationic lipid, dioleoyl phosphatidyl ethanoamines (DOPE) [50], 1,2- dioleoyl-3-trimethyl ammonium-propane (DOTAP) [51], and the stable nucleic acid liposome nanoparticles (SNALP) [52].”
Background
AttenuatedSalmonella choleraesuis-mediated RNAi targeted to conserved regions against foot-and-mouth disease virus in guinea pigs and swine
Cong, W., Jin, H. R., Jiang, C., Yan, W., Liu, M., Chen, J., Zuo, X., & Zheng, Z. (2010) · Veterinary Research · doi:10.1051/vetres/2010002 · Cited by 11
“Liposome formulations are generally used [3, 15, 49] , but a simple intranasal administration of naked siRNA has been shown to be effective against respiratory viruses [3] .”
Background
Nucleic Acid Delivery via Polymer Vehicles
Reineke, T. M., & Davis, M. E. (2012) · Elsevier eBooks · doi:10.1016/b978-0-444-53349-4.00239-9 · Cited by 13
Therapeutic modalities
Rang, H. P., LeVine, H., & Hill, R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7020-4299-7.00003-2 · Cited by 11
Delivery of RNAi mediators
Ford, L. P., & Toloue, M. (2010) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.12 · Cited by 11
“[9] [10] [11] [12] [13] [14] The liver's active filter function allows it to be easily targeted through intravenous injection and the liver is an important site for metastasis, and has several disease targets including hepatitis-B virus, hepatitis-C virus, and several genes involved in lipid and glucose metabolism.”
Background
Safety concerns raised over RNA interference
Frantz, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2104 · Cited by 11
Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?
Angelice, G. P., Roque, P. H. D. C., Valente, G., Galvão, K., Villar, L. M., Mello, V. M., Mello, F. C. D. A., & do Lago, B. V. (2024) · Viruses · doi:10.3390/v16111710 · Cited by 12
RNA interference technology with emphasis on delivery vehicles—prospects and limitations
Prabha, S., Vyas, R., Gupta, N., Ahmed, B., Chandra, R., & Nimesh, S. (2015) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2015.1058808 · Cited by 10
“Though these successful research studies on animal models for systemic delivery to non-human primates have been a much awaited boost for scientists in the field, a number of hurdles and concerns must be overcome before RNAi can be harnessed as a new therapeutic modality (Zimmermann et al. 2006).”
Background
Therapeutic siRNAs and nonviral systems for their delivery
Glebova, K. V., Владимирович, М. А., Baranova, A. V., & Skoblov, M. Y. (2012) · Molecular Biology · doi:10.1134/s0026893312020069 · Cited by 10
A novel method of vesicle preparation by simple dilution of bicelle solution
Taguchi, S., Kang, B.-S., Suga, K., Okamoto, Y., Jung, H., & Umakoshi, H. (2020) · Biochemical Engineering Journal · doi:10.1016/j.bej.2020.107725 · Cited by 10
Allele-Specific Gene Silencing in Osteogenesis Imperfecta
Ljunggren, Ö., Lindahl, K., Rubin, C., & Kindmark, A. (2011) · Endocrine development · doi:10.1159/000328133 · Cited by 10
Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver
Maczuga, P., Verheij, J., van der Loos, C. M., van Logtenstein, R., Hooijer, G. K. J., Martier, R., Borel, F., Lubelski, J., Koornneef, A., Blits, B., et al. (2013) · Gene Therapy · doi:10.1038/gt.2013.58 · Cited by 10
Current Status of siRNA Delivery Technology and siRNA Drug Development
Urakami, T., & Oku, N. (2007) · The Open Drug Delivery Journal · doi:10.2174/1874126600701010020 · Cited by 10
A Novel Nonviral Gene Delivery System: Multifunctional Envelope-Type Nano Device
Hatakeyama, H., Akita, H., Kogure, K., & Harashima, H. (2009) · Springer eBooks · doi:10.1007/10_2008_40 · Cited by 10
Lysosomal Storage Disease-Associated Neuropathy: Targeting Stable Nucleic Acid Lipid Particle (SNALP)-Formulated siRNAs to the Brain as a Therapeutic Approach
Coutinho, M. F., Santos, J. I., Mendonça, L. S., Matos, L., Prata, M. J., Jurado, A. S., de Lima, M. C. P., & Alves, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165732 · Cited by 10
siRNA Therapeutics for Protein Misfolding Diseases of the Central Nervous System
Zabel, M. D., Mollnow, L., & Bender, H. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1298-9_20 · Cited by 11
Targeting siRNAs in cancer drug delivery
Obeid, M. A., Aljabali, A. A. A., Alshaer, W., Charbe, N. B., Chellappan, D. K., Dua, K., Satija, S., & Tambuwala, M. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85503-7.00027-4 · Cited by 12
Antisense Inhibitors, Ribozymes, and siRNAs
Thompson, A. J. V., & Patel, K. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.05.003 · Cited by 10
“somal formulation of ApoB-specific siRNA has recently been shown to successfully silence gene expression in a primate model.(98) Although mild hepatotoxicity was observed at high doses, the technology is promising.”
Background
Enhanced Binding Affinity of siRNA Overhang‐Binding Fluorescent Probes by Conjugation with Cationic Oligopeptides for Improved Analysis of the siRNA Delivery Process
Sato, Y., Kaneko, M., Sato, T., Nakata, S., Takahashi, Y., & Nishizawa, S. (2018) · ChemBioChem · doi:10.1002/cbic.201800560 · Cited by 10
Target Validation to Biomarker Development
Colombo, R., & Moll, J. K. (2008) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256271 · Cited by 10
Local and Systemic Delivery of siRNAs for Oligonucleotides Therapy
Takeshita, F., Hokaiwado, N., Honma, K., Banaś-Ząbczyk, A., & Ochiya, T. (2008) · Methods in molecular biology · doi:10.1007/978-1-60327-547-7_4 · Cited by 10
Zebrafish larvae as a model system for systematic characterization of drugs and genes in dyslipidemia and atherosclerosisPreprint
Bandaru, M. K., Emmanouilidou, A., Ranefall, P., von der Heyde, B., Mazzaferro, E., Klingström, T., Masiero, M. M., Dethlefsen, O., Ledin, J., Larsson, A. O., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/502674 · Cited by 10
Hepatic RNA interference: delivery by synthetic vectors
Haynes, M. T., & Huang, L. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0157-8 · Cited by 9
“5 mg/kg dose eliciting 90 % mRNA knockdown, maintaining knockdown for 11 days, and reduced serum cholesterol by over 60 % [90].”
TLR9-Targeted SiRNA Delivery In Vivo
Hossain, D. M. S., Moreira, D., Zhang, Q., Nechaev, S., Swiderski, P. M., & Kortylewski, M. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3112-5_15 · Cited by 9
Lipopeptide Delivery of siRNA to the Central Nervous System
Zabel, M. D. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-140-0_17 · Cited by 10
The intratracheal administration of locked nucleic acid containing antisense oligonucleotides induced gene silencing and an immune-stimulatory effect in the murine lung
Uemura, Y., Hagiwara, K., & Kobayashi, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187286 · Cited by 9
Fooling the Fas ligand in death
Rodrigues, C. M. P., & Steer, C. J. (2006) · Hepatology · doi:10.1002/hep.21320 · Cited by 9
Silencing of Mouse Hepatic Lanosterol 14-.ALPHA. Demethylase Down-Regulated Plasma Low-Density Lipoprotein Cholesterol Levels by Short-Term Treatment of siRNA
Xu, B., Wang, C., Yang, J., Mao, G., Zhang, C., Liu, D., Tai, P., Zhou, B., Xia, G., & Zhang, M. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.1182 · Cited by 9
New short interfering RNA-based therapies for glomerulonephritis
Shimizu, H., & Fujita, T. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.61 · Cited by 9
Chemical crosshairs on the central dogma
Ansari, A. Z. (2006) · Nature Chemical Biology · doi:10.1038/nchembio0107-2 · Cited by 9
Quick nuclear transportation of siRNA and in vivo hepatic ApoB gene silencing with galactose-bearing polymeric carrier
Tachibana, Y., Munisso, M. C., Kamata, W., Kitagawa, M., Harada‐Shiba, M., & Yamaoka, T. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.01.029 · Cited by 9
Inter-molecular β-sheet structure facilitates lung-targeting siRNA delivery
Zhou, J., Li, D., Wen, H., Zheng, S., Su, C., Fan, Y., Wang, J., Liang, Z., Tang, T., Zhou, D., et al. (2016) · Scientific Reports · doi:10.1038/srep22731 · Cited by 9
Nanomedicine in cardiology: Precision drug delivery for enhanced patient outcomes
Peng, F., Wang, Z., Qiu, Z., Zhang, W., Zhao, Y., Li, C., & Shi, B. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123199 · Cited by 9

Authors: Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., Judge, A. D., Lam, K., McClintock, K., Nechev, L. V., Palmer, L. R., Racie, T., Röhl, I., Seiffert, S., Shanmugam, S., Sood, V., Soutschek, J., Toudjarska, I., Wheat, A. J., Yaworski, E., Zedalis, W., Koteliansky, V., Manoharan, M., Vornlocher, H.-P., & MacLachlan, I.
Affiliations: Alnylam Pharmaceuticals (United States) (US)
Electronic Arts (Canada) (CA)
Corresponding author: Zimmermann, Tracy S.
MacLachlan, Ian
ORCID: Lee, Amy C. H.
Fedoruk, Matthew N.
Harborth, Jens
Heyes, James A.
Lam, Kieu
McClintock, Kevin
Palmer, Lorne R.
Manoharan, Muthiah
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2006-03-26
Volume: 441
Issue: 7089
Pages: 111-114
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature04688
OpenAlex: W2095151181
Cited by: 1,357
References: 20
Citations by year: 2026: 21 · 2025: 22 · 2024: 30 · 2023: 42 · 2022: 40 · 2021: 35 · 2020: 35 · 2019: 46 · 2018: 30 · 2017: 47 · 2016: 54 · 2015: 70 · 2014: 97 · 2013: 113 · 2012: 111
FWCI: 46.06
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Alnylam Pharmaceuticals
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords: RNA interference, gene silencing, siRNA, apolipoprotein B, siRNA therapeutics, systemic siRNA delivery, Macaca fascicularis, non-human primates, hypercholesterolemia, LDL cholesterol, B-cell lymphoma, CARD11
MeSH terms: Animals, Apolipoproteins B, Phenotype, Primates, RNA, Messenger, RNA Interference, RNA, Small Interfering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

RNAi-mediated gene silencing in non-human primates

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks